Who is sponsoring NCT05984017?

NCT05984017 is sponsored by Hunan Province Tumor Hospital.

What drugs are being tested in NCT05984017?

Interventions in NCT05984017: No treatment is included in this study.

What condition does NCT05984017 study?

NCT05984017 studies Advanced Lung Squamous Cell Carcinoma.

Is NCT05984017 still recruiting?

NCT05984017 is currently status unknown. Last updated 10 January 2024.

Last reviewed 2024-01-10 · How we verify

NCT05984017

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma

Status unknown Last updated 10 January 2024

What this trial tests

trial testing No treatment is included in this study in Advanced Lung Squamous Cell Carcinoma in 130 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Hunan Province Tumor Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	130
Start date	1 July 2021
Primary completion	31 December 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

No treatment is included in this study

Conditions studied

Advanced Lung Squamous Cell Carcinoma — all drugs for Advanced Lung Squamous Cell Carcinoma →

Sponsor

Hunan Province Tumor Hospital

Who can join

18 and older, any sex, with Advanced Lung Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hunan Province Tumor Hospital trials

Trials by the same sponsor.

NCT06706219 — Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unres · Phase 2 · not yet recruiting
NCT07001995 — Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression · Phase 2 · not yet recruiting
NCT07477808 — Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07251582 — Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05984017 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hunan Province Tumor Hospital
Last refreshed: 10 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05984017.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing